XYLOBIOSE

CAS No. 6860-47-5

XYLOBIOSE( —— )

Catalog No. M20482 CAS No. 6860-47-5

XYLOBIOSE ia a natural productand exhibited therapeutic potential for treating obesity which involved suppression of fat deposition and obesity-related metabolic disorders.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 69 In Stock
10MG 97 In Stock
25MG 161 In Stock
50MG 239 In Stock
100MG 356 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    XYLOBIOSE
  • Note
    Research use only, not for human use.
  • Brief Description
    XYLOBIOSE ia a natural productand exhibited therapeutic potential for treating obesity which involved suppression of fat deposition and obesity-related metabolic disorders.
  • Description
    XYLOBIOSE ia a natural productand exhibited therapeutic potential for treating obesity which involved suppression of fat deposition and obesity-related metabolic disorders.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    TNF-α|IL-1β
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    6860-47-5
  • Formula Weight
    282.24
  • Molecular Formula
    C10H18O9?
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?H2O : 250 mg/mL (885.77 mM)
  • SMILES
    O[C@@H]1CO[C@@H](O[C@@H]2COC(O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O
  • Chemical Name
    D-Xylose 4-O-beta-D-xylopyranosyl-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Soo-Min L Eunju K Jae-Ho S et al. Xylobiose Prevents High-Fat Diet Induced Mice Obesity by Suppressing Mesenteric Fat Deposition and Metabolic Dysregulation[J]. Molecules 2018 23(3):705-.
molnova catalog
related products
  • Certolizumab pegol

    Certolizumab pegol (Certolizumab) is a polyethylene glycolated and humanized anti-TNF-α monoclonal antibody for the study of autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).

  • GSK3145095

    GSK3145095 is an orally active inhibitor of RIPK1 with IC50 of 5 nM, with potential immunomodulatory activities and antineoplastic.

  • XYLOBIOSE

    XYLOBIOSE ia a natural productand exhibited therapeutic potential for treating obesity which involved suppression of fat deposition and obesity-related metabolic disorders.